U.S. markets closed

Sanofi (SAN.PA)

Paris - Paris Precio retrasado. Divisa en EUR.
Añadir a la lista de seguimiento
90.00+0.84 (+0.94%)
Al cierre: 05:35PM CEST

Sanofi

46, avenue de la Grande Armée,
Paris 75017
France
33 1 53 77 40 00
https://www.sanofi.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - General
Empleados a tiempo completo86,088

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Paul HudsonCEO & Director3.79MN/D1967
Mr. François-Xavier RogerExecutive VP & CFON/DN/D1962
Ms. Madeleine RoachExecutive VP & Head of Business OperationsN/DN/D1984
Mr. Laurent GilhodesPrincipal Accounting Officer and Vice President of Corporate AccountingN/DN/DN/D
Dr. Josephine FubaraChief Science Officer of Consumer Health CareN/DN/DN/D
Eva Schaefer-JansenHead of Investor RelationsN/DN/DN/D
Mr. Dante BeccariaGlobal Compliance Officer & VPN/DN/DN/D
Mr. Roy PapatheodorouExecutive VP & General CounselN/DN/D1978
Mr. Josep CatllaHead of CommunicationsN/DN/DN/D
Mr. Pierre ChancelSenior Vice President of Global Diabetes and Senior Vice President of Global MarketingN/DN/D1957
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Gestión corporativa

La calificación ISS Governance QuickScore de Sanofi a partir del 1 de mayo de 2024 es 2. Las puntuaciones principales son Auditoría: 4; Junta: 2; Derechos del accionista: 5; Compensación: 2.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.